{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:53:56Z","timestamp":1791726836195,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ophtha.2022.01.015","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T13:13:23Z","timestamp":1642598003000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema"],"prefix":"10.1016","volume":"129","author":[{"given":"Michael A.","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-9947","authenticated-orcid":false,"given":"Veeral","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam E.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Coughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2022.01.015_bib1","first-page":"2156273","article-title":"Diabetic macular edema pathophysiology: vasogenic versus inflammatory","volume":"2016","author":"Romero-Aroca","year":"2016","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.ophtha.2022.01.015_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: beyond the surface","volume":"63","author":"Daruich","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.ophtha.2022.01.015_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2022.01.015_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"issue":"4","key":"10.1016\/j.ophtha.2022.01.015_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/ijms19040942","article-title":"Role of inflammation in diabetic retinopathy","volume":"19","author":"Rubsam","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ophtha.2022.01.015_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/OPTH.S206769","article-title":"Dexamethasone implant in the management of diabetic macular edema from clinician\u2019s perspective","volume":"13","author":"Urbancic","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2022.01.015_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2022.01.015_bib8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/OPTH.S114006","article-title":"Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema","volume":"10","author":"Kiss","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2022.01.015_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.01.015_bib10","unstructured":"Bailey C, Chakravarthy U, Lotery A, et al. Clinical trial outcomes with ILUVIEN\u00ae (fluocinolone acetonide) in the treatment of chronic diabetic macular oedema (DMO) are predictive of real-world outcomes after 24 months of continuous therapy. Poster presented at: The Controversies in Ophthalmology (COPHy) 8th World Congress; March 30-April 1, 2017; Madrid, Spain."},{"issue":"12","key":"10.1016\/j.ophtha.2022.01.015_bib11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ophtha.2022.01.015_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/0974-9233.92116","article-title":"Diabetic retinopathy and inflammation: novel therapeutic targets","volume":"19","author":"Rangasamy","year":"2012","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2022.01.015_bib13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema","volume":"152","author":"Sohn","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.01.015_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.exer.2016.08.005","article-title":"Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in\u00a0vitro","volume":"151","author":"Stewart","year":"2016","journal-title":"Exp Eye Res"},{"issue":"12","key":"10.1016\/j.ophtha.2022.01.015_bib15","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","article-title":"Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations","volume":"35","author":"Yang","year":"2015","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ophtha.2022.01.015_bib16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","article-title":"Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.01.015_bib17","series-title":"Inc. Iluvien [package insert]","year":"2014"},{"issue":"10","key":"10.1016\/j.ophtha.2022.01.015_bib18","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2022.01.015_bib19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3928\/23258160-20160419-05","article-title":"Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials","volume":"47","author":"Parrish","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"10.1016\/j.ophtha.2022.01.015_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40123-018-0155-5","article-title":"The USER Study: a chart review of patients receiving a 0.2 microg\/day fluocinolone acetonide implant for diabetic macular edema","volume":"8","author":"Eaton","year":"2019","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"10.1016\/j.ophtha.2022.01.015_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3928\/23258160-20200501-09","article-title":"Reduction in retinal thickness fluctuations after treatment with fluocinolone acetonide implant for DME: a post-hoc analysis of the USER Study","volume":"51","author":"Riemann","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.ophtha.2022.01.015_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/bjophthalmol-2020-315984","article-title":"Two-year interim safety results of the 0.2 microg\/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study","volume":"105","author":"Mansour","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2022.01.015_bib23","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2022.01.015_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A\u00a0computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2022.01.015_bib25","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamaophthalmol.2019.4284","article-title":"Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial","volume":"137","author":"Hutton","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2022.01.015_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/aes.2018.09.05","article-title":"Diabetic retinopathy: an inflammatory disease","volume":"3","author":"Vujosevic","year":"2018","journal-title":"Ann Eye Sci"},{"key":"10.1016\/j.ophtha.2022.01.015_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1755-8794-2-58","article-title":"Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells","volume":"2","author":"Nehme","year":"2009","journal-title":"BMC Med Genomics"},{"issue":"16","key":"10.1016\/j.ophtha.2022.01.015_bib28","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ophtha.2022.01.015_bib29","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2022.01.015_bib30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3928\/23258160-20201104-10","article-title":"Effects of long-term DME control with 0.2 microg\/day fluocinolone acetonide implant on quality of life: an exploratory analysis from the FAME Trial","volume":"51","author":"Singer","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.ophtha.2022.01.015_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2022.01.015_bib34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2022.01.015_bib36","first-page":"1","article-title":"Combination treatment of diabetic macular edema with anti-vascular endothelial growth factor and steroids: analysis of DRCR.net protocol U","volume":"1","author":"Ung","year":"2018","journal-title":". Am J Ophthalmic Clinical Trials"},{"issue":"6","key":"10.1016\/j.ophtha.2022.01.015_bib37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Diabetic Retinopathy Clinical Research Network","year":"2010","journal-title":"Ophthalmology"}],"updated-by":[{"DOI":"10.1016\/j.ophtha.2025.03.030","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642022000677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642022000677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:11:10Z","timestamp":1758982270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642022000677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0161642022000677"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.01.015","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}